

Bezafibrate

Catalog No: tcsc2874



Available Sizes

Size: 100mg



Specifications

CAS No:

41859-67-0

Formula:

$C_{19}H_{20}ClNO_4$

Pathway:

Cell Cycle/DNA Damage

Target:

PPAR

Purity / Grade:

>98%

Solubility:

DMSO : ≥ 50 mg/mL (138.19 mM)

Alternative Names:

BM15075

Observed Molecular Weight:

361.82


Product Description

Bezafibrate is an agonist of **PPAR**, with **EC₅₀**s of 50 μ M, 60 μ M, 20 μ M for **human PPAR α** , **PPAR γ** and **PPAR δ** , and 90 μ M, 55 μ M, 110 μ M for **murine PPAR α** , **PPAR γ** and **PPAR δ** , respectively; Bezafibrate is used as an hypolipidemic agent.

IC50 & Target: EC50: 90 μ M (Murine PPAR α), 55 μ M (Murine PPAR γ), 110 μ M (Murine PPAR δ), 50 μ M (Human PPAR α), 60 μ M (Human PPAR γ), 20 μ M (Human PPAR δ)^[1]

In Vitro: Bezafibrate is an agonist of PPAR, with EC₅₀s of 90 μ M, 55 μ M, 110 μ M for murine PPAR α , PPAR γ and PPAR δ , and 50 μ M, 60 μ M, 20 μ M for human PPAR α , PPAR γ and PPAR δ , respectively^[1]. Bezafibrate (> 200 μ M) shows significant cytotoxicity against human retinal microvascular endothelial cells (HRMECs) and human retinal pigment epithelial ARPE-19 cells. Bezafibrate (30-100 μ M) suppresses tumor necrosis factor (TNF) α induced inflammatory factors and regulates TNF α induced nuclear factor (NF)- κ B transactivation in HRMEC. Bezafibrate inhibits VEGF-induced HRMECs migration, and inhibits interleukin (IL)-1 β -induced VEGF secretion of ARPE-19 cells^[2].

In Vivo: Bezafibrate (0.5%) markedly reduces plasma lipid and glucose levels, and increases islet area in the pancreas in TallyHo mice. Bezafibrate also improves energy expenditure and metabolic flexibility. Moreover, Bezafibrate ameliorates steatosis, modifies lipid composition and increases mitochondrial mass in the liver^[3].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!